Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SinoMab Bioscience Ltd. ( (HK:3681) ) has shared an update.
SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of its novel monoclonal antibody, SM17, in a bridging study in China. This study aims to evaluate the safety, tolerability, and pharmacokinetics of SM17, which targets the IL-25 receptor to modulate immune responses in autoimmune and inflammatory diseases. The subcutaneous form of SM17 is expected to improve patient compliance and administration convenience, positioning it as a potentially safer and more effective treatment for atopic dermatitis compared to existing therapies.
The most recent analyst rating on (HK:3681) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company focused on the development of therapeutic antibodies. It operates in the pharmaceutical industry, with a primary focus on creating innovative treatments for autoimmune and inflammatory diseases. The company’s market focus includes addressing unmet medical needs in conditions such as atopic dermatitis.
Average Trading Volume: 20,494,220
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.43B
For detailed information about 3681 stock, go to TipRanks’ Stock Analysis page.